Entering text into the input field will update the search result below

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2019 Results - Earnings Call Transcript

Mar. 02, 2020 2:01 PM ETEagle Pharmaceuticals, Inc. (EGRX)
SA Transcripts profile picture
SA Transcripts

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2019 Results Conference Call March 2, 2020 8:30 AM ET

Company Participants

Lisa Wilson - IR

Scott Tarriff - CEO

Pete Meyers - CFO

Conference Call Participants

Zach Sachar - Piper Sandler

Randall Stanicky - RBC Capital Markets

Lachlan Hanbury-Brown - William Blair

Brandon Folkes - Cantor Fitzgerald

Gregg Gilbert - SunTrust


Good day, and welcome to today's program. My name is Brie, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals Fourth Quarter and Full Year 2019 Earnings Results Conference Call. All lines will be placed on mute to prevent any background noise. [Operator Instructions]

As a reminder, this conference call is being recorded today, March 2, 2020. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, Brie. Welcome to Eagle Pharmaceuticals fourth quarter 2019 earnings call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle Pharmaceuticals’ Chief Executive Officer, Scott Tarriff; and Chief Financial Officer, Pete Meyers.

This morning, the Company issued a press release, detailing financial results for the 3 and 12 ended December 31, 2019. This press release and a webcast of this call can be accessed through the Investors section of the Eagle website, at eagleus.com.

Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation and projection, forecast, anticipation or intent regarding future statements and the Company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act.

These forward-looking statements are based on information available to Eagle Pharmaceuticals management as of today and involve risks and uncertainties, including

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.